Privately-held BioAegis Therapeutics has announced that researchers have identified a previously unknown role of the protein gelsolin in regulating immune responses. BioAegis’s therapeutic focus is to restore waning gelsolin levels associated with disease. In a paper published in The Journal of Immunology, researchers reported that the gelsolin is involved in a signaling system in macrophages, which…
BioAegis announces promising data in case study involving critical COVID-19 patient
BioAegis (North Brunswick, NJ) is evaluating data from a Phase 2 clinical trial related to recombinant human plasma gelsolin (rhu-pGSN) along with standard of care in treating patients with severe COVID-19 pneumonia. In the interim, the company has announced the results of a compassionate use case study involving a hospitalized patient with critical COVID-19 pneumonia.…